Myogen enrolls ambrisentan PAH Phase III

MYOG completed enrollment of 187 patients in the double-blind, placebo-controlled, international Phase III ARIES-2 trial of ambrisentan to treat pulmonary arterial hypertension (PAH). The primary endp...